Imara (IMRA -13.6%) presents
interim results from its ongoing Phase 2a clinical trial of IMR-687 in
adult patients with sickle cell disease (SCD) at the 25th European
Hematology Association Annual Congress.
The data demonstrated that IMR-687, a highly
selective and potent small molecule inhibitor of PDE9 was safe and well
tolerated as a monotherapy and in combination with hydroxyurea (HU).
In the higher dose cohort, IMR-687 monotherapy
showed a statistically significant (p=0.022) increase in the number of
F-cells, which are red blood cells containing fetal hemoglobin (HbF)
compared to placebo after 24 weeks of dosing.
A dose-dependent increase in HbF levels in adult patients with SCD in the monotherapy arm was also observed.
IMR-687 was well tolerated. There was no hypotension or neutropenia observed in either the monotherapy or combination arms.
https://seekingalpha.com/news/3582642-imara-reports-positive-imrminus-687-data-in-sickle-cell-disease
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.